Carboplatin-cyclophosphamide Combined With Atezolizumab

Sponsor
The Netherlands Cancer Institute
Study ID
NCT02914470
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.

Key Dates

Start date
Jan 31, 2017
Status verified
Oct 2021
Primary completion
Aug 31, 2017
Completion
Oct 31, 2021

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: carbo, cyclo, atezolizumab
    The starting dose is carboplatin AUC 5mg/ml\*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously

Primary Outcome Measure

Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03 [ Time Frame: up to 30 days after end of treatment ]

Related Studies